Should I Buy EIKN? EIKN 2026 Analysis

Should You Buy Eikon Therapeutics Inc (EIKN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

11.820

1 Day change

7.65%

52 Week Range

Analysis Updated At

2026/03/20

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Eikon Therapeutics Inc is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive analyst ratings and a promising pipeline, the lack of significant trading trends, absence of recent news, and no proprietary trading signals suggest waiting for more clarity on the company's financial performance and market trends before making an investment decision.

Technical Analysis

The stock closed at $11.22, down 6.47% during the regular market session but recovered slightly with a 2.19% post-market gain. However, no clear trend data is available for further analysis.

Positive Catalysts

The company's innovative drug discovery platform and advanced oncology pipeline are viewed as long-term growth drivers.

Neutral/Negative Catalysts

Wedbush's Underperform rating with a $7 price target highlights concerns about the company's lead program and clinical risks. Additionally, no significant hedge fund, insider, or congress trading activity has been observed recently.

Financial Performance

No financial data or valuation metrics are available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are largely positive, with five firms initiating coverage with Overweight/Buy ratings and price targets between $26 and $34. However, Wedbush issued an Underperform rating with a $7 price target, citing concerns about the company's lead programs and clinical risks.

0 Analyst Rating

Wall Street analysts forecast EIKN stock price to rise

0 Buy

0 Hold

0 Sell

Current: 10.980

Low

Averages

High

Current: 10.980

Low

Averages

High

Cantor Fitzgerald

Overweight

initiated

AI Analysis

2026-03-02

Reason

Cantor Fitzgerald

Price Target

AI Analysis

2026-03-02

initiated

Overweight

Reason

Cantor Fitzgerald initiated coverage of Eikon Therapeutics with an Overweight rating. Eikon is a development-stage oncology company built around a novel super-resolution microscopy discovery platform, though near-term value is driven by its clinical pipeline, including PARP1-selective inhibitors with potential best-in-class positioning and a high-risk/high-reward TLR7/8 agonist in Phase 2/3 studies, the analyst tells investors in a research note. Following a $381M IPO and with $725M in pro forma cash, the company trades at a minimal enterprise value, supported by a seasoned leadership team and multiple long-term catalysts, while its platform represents additional upside not reflected in valuation, the firm says.

Morgan Stanley

Sean Laaman

Overweight

initiated

$32

2026-03-02

Reason

Morgan Stanley

Sean Laaman

Price Target

$32

2026-03-02

initiated

Overweight

Reason

Morgan Stanley analyst Sean Laaman initiated coverage of Eikon Therapeutics with an Overweight rating and $32 price target. Eikon is a late-stage clinical company with a focus on oncology, the analyst tells investors in a research note. The firm says the company's data to date are supportive of "early de-risking" of the company's clinical-stage assets. It says Eikon's multiple data readouts across the pipeline in the second half of 2026 "create clear opportunities for upside."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EIKN

Unlock Now

EIKN Should I Buy

EIKN Should I Buy

Should You Buy Eikon Therapeutics Inc (EIKN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch